首页> 外文OA文献 >A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

【2h】

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

机译：Neoadjuvant Letrozole的II期随机研究加上激素受体阳性，人表皮生长因子受体2阴性乳腺癌（Neo-Orb）的alpelisib

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Ingrid A. Mayer; Aleix Prat; Daniel Egle; Sibel Blau; J. Alejandro Pérez Fidalgo; Michael Gnant; Peter A. Fasching; Marco Colleoni; Antonio C. Wolff; Eric P. Winer; Christian F. Singer; Sara Hurvitz; Laura García Estévez; Peter A. van Dam; Sherko Kümmel; Christoph Mundhenke; Frankie Holmes; Naveen Babbar; Laure Charbonnier; Ivan Diaz-Padilla; Florian D. Vogl; Dalila Sellami; Carlos L. Arteaga;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) [J] . Mayer Ingrid A., Prat Aleix, Egle Daniel, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第10期

机译：Neoadjuvant Letrozole的II期随机研究加上激素受体阳性，人表皮生长因子受体2阴性乳腺癌（Neo-Orb）的alpelisib
2. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. [J] . Valentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, Journal of Clinical Oncology . 2014,第10期

机译：双盲，安慰剂控制，多中心，随机，阶段IIB Neoadjuvant研究Letrozole-lapatinib在绝经后激素受体阳性，人表皮生长因子受体2阴性，可操作的乳腺癌。
3. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. [J] . Valentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, Journal of Clinical Oncology . 2014,第10期

机译：双盲，安慰剂控制，多中心，随机，阶段IIB Neoadjuvant研究Letrozole-lapatinib在绝经后激素受体阳性，人表皮生长因子受体2阴性，可操作的乳腺癌。
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [O] . Ingrid A. Mayer, Vandana G. Abramson, Steven J. Isakoff, -1

机译：在雌激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中接受泛磷酰胺3-激酶抑制剂布帕利西普与来曲唑的癌症Ib期研究
7. Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer [O] . Guarneri Valentina, Generali Daniele, Frassoldati Antonio, 2014

机译：来曲唑-拉帕替尼治疗绝经后激素受体阳性，人表皮生长因子受体2-阴性，可手术的乳腺癌的双盲，安慰剂对照，随机，IIB期新辅助研究

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

著录项

引文网络

相似文献

相关主题

期刊订阅